- Clinician Scientist, KGHRI
- Associate Professor, Echocardiography, Queen’s University
- Founder & Director, Cardiovascular Imaging Network at Queen’s (CINQ
Dr. Johri’s particular interest is in 3D echocardiography, quality control in the echo lab, interventional echocardiography, hand-held cardiac and vascular ultrasound, and carotid plaque and strain assessment. He also has extensive experience in echo-guided CRT optimization and TEE guided percutaneous aortic valve replacement (TAVI). He serves as an executive member of the ASE Standards and Guidelines Committee is actively participating in the development and review this society's position statement on Hand-Held Cardiac Ultrasound. He is a SEAMO and Heart and Stroke funded clinical scientist.
Education and honours
- Doctor of Medicine, Queen’s University
- Master of Science, McMaster University
- Cardiology FRCPC, Internal Medicine FRCPC, Queen’s University
- Fellow of the American Society of Echocardiography, Harvard University
- 2016 Ontario Research Fund Early Researcher Award
Dr. Johri joined the Echocardiography group at Queen’s University in 2010 after completing an Advanced Fellowship in Echocardiography (Level III) and Multi-modality Imaging at Harvard University Medical School, Boston MA. He is the Founder/Director of the Cardiovascular Imaging Network at Queen's (CINQ) and has the distinction of Fellow of the American Society of Echocardiography (ASE) in recognition of his various contributions to the advancement of the field of ultrasound.
Dr. Johri’s current research interests include the investigation of carotid intimal medial thickening, atherosclerotic plaque quantification, carotid strain, 3D cardiac strain, and 3D stress testing. His laboratory focuses on the innovation of non-invasive techniques to predict and diagnose atherosclerotic cardiovascular disease with a focus on three-dimensional carotid ultrasound. Ultrasound is used for: assessment of carotid plaque for early detection of atherosclerotic cardiovascular disease (ACVD), enhancing the stress echocardiogram to better predict significant ACVD, integrating genetic biomarkers to predict ACVD, and monitoring response to treatment of ACVD using novel pharmacologic agents. His laboratory is supported by the Canada Foundation for Innovation, the SEAMO Clinical Scientist Development Program, and The Heart and Stroke Foundation of Canada.